Invesco
CCCC icon

Invesco’s C4 Therapeutics CCCC Stock Holding History

Invesco’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
290,226
+45,719
+19% +$156K ﹤0.01% 2762
2026
Q1 		$643K Sell
244,507
-23,843
-9% -$56.1K ﹤0.01% 3051
2025
Q4 		$513K Buy
268,350
+76,530
+40% +$181K ﹤0.01% 3187
2025
Q3 		$426K Buy
191,820
+36,803
+24% +$88.3K ﹤0.01% 3296
2025
Q2 		$222K Buy
155,017
+15,531
+11% +$22.6K ﹤0.01% 3485
2025
Q1 		$223K Buy
139,486
+70,293
+102% +$210K ﹤0.01% 3471
2024
Q4 		$249K Buy
69,193
+4,647
+7% +$23.1K ﹤0.01% 3468
2024
Q3 		$368K Sell
64,546
-953
-1% -$5.74K ﹤0.01% 3349
2024
Q2 		$303K Buy
65,499
+26,963
+70% +$161K ﹤0.01% 3497
2024
Q1 		$315K Sell
38,536
-653,546
-94% -$5.07M ﹤0.01% 3508
2023
Q4 		$3.91M Buy
692,082
+635,691
+1,127% +$1.45M ﹤0.01% 2355
2023
Q3 		$105K Buy
56,391
+481
+0.9% +$1.47K ﹤0.01% 3709
2023
Q2 		$154K Sell
55,910
-13,549
-20% -$43.5K ﹤0.01% 3662
2023
Q1 		$218K Buy
69,459
+53,233
+328% +$313K ﹤0.01% 3607
2022
Q4 		$95.7K Sell
16,226
-30
-0.2% -$249 ﹤0.01% 3833
2022
Q3 		$142K Buy
16,256
+2,401
+17% +$24.9K ﹤0.01% 3767
2022
Q2 		$105K Sell
13,855
-124,557
-90% -$1.1M ﹤0.01% 3877
2022
Q1 		$3.36M Sell
138,412
-325,790
-70% -$7.91M ﹤0.01% 2568
2021
Q4 		$14.9M Sell
464,202
-6,321
-1% -$250K ﹤0.01% 1747
2021
Q3 		$21M Buy
470,523
+1,128
+0.2% +$48.3K 0.01% 1536
2021
Q2 		$17.8M Sell
469,395
-140,324
-23% -$5.03M ﹤0.01% 1695
2021
Q1 		$22.6M Buy
609,719
+309,177
+103% +$12.3M 0.01% 1455
2020
Q4 		$9.96M Buy
+300,542
New +$8.72M ﹤0.01% 1816

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco's CCCC Position: Q2 2026 in Review

Invesco increased its C4 Therapeutics (CCCC) stake by 19% in Q2 2026, buying an estimated $156K and bringing the position to 290,226 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2762.

Invesco first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $22.6M in Q1 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Invesco held 290,226 shares of C4 Therapeutics worth $1.36M as of Q2 2026.
  • Invesco bought 45,719 C4 Therapeutics shares in Q2 2026, an estimated $156K.
  • C4 Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2762 holding.
  • Invesco first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Invesco's C4 Therapeutics position peaked at $22.6M in Q1 2021.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.